Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Final Progress Reports: Oregon State University: PAHs in Humans at Environmental Levels: Pharmacokinetics, Metabolism and Susceptible Individuals

Superfund Research Program

PAHs in Humans at Environmental Levels: Pharmacokinetics, Metabolism and Susceptible Individuals

Project Leader: David E. Williams
Grant Number: P42ES016465
Funding Period: 2013-2020
View this project in the NIH Research Portfolio Online Reporting Tools (RePORT)

Project-Specific Links

Connect with the Grantees

Visit the grantee's eNewsletter page Visit the grantee's eNewsletter page Visit the grantee's Twitter page Visit the grantee's Facebook page Visit the grantee's Video page

Final Progress Reports

Year:   2019 

Benzo[a]pyrene (BaP), an International Agency for Research on Cancer class one known human carcinogen, also exhibits cardiovascular, developmental, behavioral, neurocognitive, immunological, and reproductive toxicity. Polycyclic Aromatic Hydrocarbons (PAHs), from combustion of carbon (coal, diesel, tobacco, etc.), comprise three of the top ten chemicals of concern (Agency for Toxic Substances and Disease Registry) at priority pollutant sites and are main drivers of remediation. The EPA cancer risk slope factor is one (mg/kg-day). BaP is the EPA reference compound for cancer risk assessment with PAH mixtures (Relative Potency Factor, BaP=1) and drives remediation goals. Risk estimates are from predominantly mouse models. The remarkable sensitivity (zepto-attomole 14C in biological samples) of accelerator mass spectrometry (AMS) makes possible, with de minimus risk, pharmacokinetic (PK) analysis following [14C]-BaP micro-dosing of humans. A 46 ng (5 nCi) dose was given three to five volunteers with minimum two weeks between dosing and plasma collected over 72 hours. [14C]-BaPeq PK analysis gave plasma T-max and C-max values of 1.25 h and 29-82 fg/mL, respectively. PK parameters were assessed by non- compartment and compartment models. The RPF approach was tested by co-administration of a complex PAH mixture from smoked salmon and the impact of genotype on metabolic profile (Hummel et al., 2018). Major findings were that there is little intra-individual variation, and rapid absorption with extensive metabolism with distinct individual metabolite profiles (Madeen et al., 2019). Finally, there were no detectable BaP-DNA adducts in PBMCs (LOD 0.5 x 10^11 adducts/nucleotide) after 48-72 hours. These results can be incorporated into risk assessment models to set remediation targets driven by human data.

to Top